InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,131.48
(
-0.29%
)
Post# of 252498
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: Titan V post# 205042

Saturday, 10/08/2016 12:20:56 PM

Saturday, October 08, 2016 12:20:56 PM

Post# of 252498
Re: Bladder cancer
Heat Biologics (NASDAQ: HTBX) will be sharing phase 2 results from their HS-410 bladder cancer trial this quarter (monotherapy as well as with BCG).

Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.
https://www.ncbi.nlm.nih.gov/pubmed/?term=hs-410

HS-410 received Fast Track designation from FDA.

HS-410's phase 2 trial was a finalist for Pharma Intelligence's "Most Innovative Clinical Trial Design"
HS-410 was also a finalist for "Most Successful Early Phase Trial (Preclinical & Phase I)"
https://ibiawards.com/careawards/finalists/

Heat Biologics Corporate Presentation
http://content.stockpr.com/heatbio/media/3848f8c4739fa3f88470f3337f8369f9.pdf

Q&A with CEO Jeffrey Wolf
http://thebioconnection.com/qa-heat-biologics-founder-ceo-jeffrey-wolf-t-cell-stimulating-cancer-immunotherapies/
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up